A Phase 3 interventional study of Placebo and Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease, sponsored by United Therapeutics. Completed at 108 sites in 16 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Idiopathic Pulmonary Fibrosis with a site in France — 10 open to participants now, 16 under way, 5 of them phase 3. Idiopathic Pulmonary Fibrosis · France.
Among the 70 studies in Idiopathic Pulmonary Fibrosis with a site in France, this one is the 9th largest by enrollment of the 57 interventional ones that give a count, is one of 7 that started in 2022, is one of 16 in phase 3, and was the 45th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →10 of the 70 studies in Idiopathic Pulmonary Fibrosis with a site in France are open now. Recruiting first, the newest first:
AstraZeneca · Sites in France, United States, Argentina and 20 more countries
Ages 40+
AbbVie · Sites in France, United States, Australia and 14 more countries
Ages 40+
Contineum Therapeutics · Sites in France, Argentina, Australia and 16 more countries
Ages 40+
Avalyn Pharma Inc. · Sites in France, United States, Argentina and 10 more countries
Ages 18+
Biosency · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 26 · Phase 3 17 · Phase 4 4
First in 2000; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 597 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 178 across the 57 interventional studies, 141 across the 13 observational. Of the 49 that completed or were terminated, 26 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 70 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
United Therapeutics has 4 studies filed under Idiopathic Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
3 of the studies in Idiopathic Pulmonary Fibrosis with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT06736990Calluna Pharma ASA Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis | 2026-11 |
| NCT06967805Mediar TherapeuticsWISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF) | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 70 studies in Idiopathic Pulmonary Fibrosis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study RIN-PF-303 is a multinational study designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Study RIN-PF-303 is a multinational, randomized, double-blind, placebo-controlled study to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute FVC in subjects with idiopathic pulmonary fibrosis (IPF) over a 52-week period. Subjects will be randomly allocated 1:1 to receive inhaled treprostinil or placebo. All subjects will initiate inhaled treprostinil or placebo at a dose of 3 breaths administered 4 times daily (QID) and will titrate to a target dosing regimen of 12 breaths QID. Study drug doses may be titrated up as tolerated, until the target dose or maximum clinically tolerated dose is achieved. Once eligible, 6 Treatment Period visits to the clinic will be required at Weeks 4, 8, 16, 28, 40, and 52.
Efficacy assessments include spirometry (FVC), time to clinical worsening, time to first acute exacerbation of IPF, overall survival, King's Brief Interstitial Lung Disease (K-BILD) questionnaire, plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration, supplemental oxygen use, and lung diffusion capacity (DLCO). Safety assessments include the development of adverse events (AEs)/serious adverse events (SAEs), vital signs, clinical laboratory parameters, and electrocardiogram (ECG) parameters.
Subjects who complete the Week 52 Visit may be offered the opportunity to enter an open-label extension (OLE) study after completing the final study visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Matching placebo inhaled using an ultrasonic nebulizer QID
Drug: Placebo · Device: Treprostinil Ultrasonic Nebulizer
Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated up to a target of 12 breaths QID or until the subject reaches their maximum clinically tolerated dose.
Drug: Inhaled Treprostinil · Device: Treprostinil Ultrasonic Nebulizer
Placebo administered QID
Inhaled treprostinil (6 mcg/breath) administered QID
Also known as: Tyvaso
Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
Change in Absolute FVC From Baseline to Week 52
The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath.
Time frame: Baseline to Week 52
Time to Clinical Worsening
Clinical worsening was monitored from randomization until 1 of the following criteria were met: death (all causes), hospitalization due to a respiratory indication, or 10% relative decline in % predicted FVC. The number of participants with clinical worsening was reported. The time to first clinical worsening event was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables.
Time frame: Baseline to Week 52
Time to First Acute Exacerbation of IPF
An acute exacerbation of IPF is defined as an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality. The number of participants with an exacerbation of IPF was reported. The time to first acute exacerbation of IPF was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables.
Time frame: Baseline to Week 52
Overall Survival at Week 52
Vital status was assessed for all subjects at Week 52, including those who discontinued the study prematurely. The number of deaths by Week 52 was reported. The time to death was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables. Note: Participants who discontinued from the study early had their time to death censored at Day 373 or last contact date when known to be alive (whichever occurred first), and participants with lung transplantation had their time to death censored at lung transplant date. Therefore, the number of deaths for this outcome measure differ from the overall number on deaths (reported in the Adverse Events section).
Time frame: Baseline to Week 52
Change in % Predicted FVC From Baseline to Week 52
The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath. Percent predicted FVC is calculated based on factors such as ethnicity, sex, age, height, and weight.
Time frame: Baseline to Week 52
Change in K-BILD Total Score From Baseline to Week 52
The King's Brief Interstitial Lung Disease Questionnaire (K-BILD) is a self-administered, 15-item questionnaire validated for patients with interstitial lung disease (ILD) consisting of 3 domains (breathlessness and activities, psychological, and chest symptoms). Each of the 15 questions is scored from 1 (worst score) to 7 (best score). The scores for the 15 questions are added together and converted into a Total Score from 0 to 100. Higher scores indicate a better quality of life.
Time frame: Baseline to Week 52
Change in DLCO From Baseline to Week 52
The DLCO measurement measures how well oxygen moves from the lungs to the blood.
Time frame: Baseline to Week 52
| Milestone | Inhaled Treprostinil | Placebo |
|---|---|---|
| Started | 298 | 295 |
| Completed | 224 | 239 |
| Not completed | 74 | 56 |
| Withdrew: Adverse event | 14 | 10 |
| Withdrew: Death | 14 | 21 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Physician decision | 3 | 2 |
| Withdrew: Withdrawal by subject | 34 | 18 |
| Withdrew: Lung transplantation | 4 | 3 |
| Withdrew: Progressive disease | 4 | 2 |
The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath.
| mL | Inhaled Treprostinil | Placebo |
|---|---|---|
| Change in Absolute FVC From Baseline to Week 52 | -49.9 (-79.2 to -19.5) | -136.4 (-172.5 to 104.0) |
Clinical worsening was monitored from randomization until 1 of the following criteria were met: death (all causes), hospitalization due to a respiratory indication, or 10% relative decline in % predicted FVC. The number of participants with clinical worsening was reported. The time to first clinical worsening event was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables.
| Participants | Inhaled Treprostinil | Placebo |
|---|---|---|
| Time to Clinical Worsening | 81 | 115 |
An acute exacerbation of IPF is defined as an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality. The number of participants with an exacerbation of IPF was reported. The time to first acute exacerbation of IPF was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables.
| Participants | Inhaled Treprostinil | Placebo |
|---|---|---|
| Time to First Acute Exacerbation of IPF | 9 | 17 |
Vital status was assessed for all subjects at Week 52, including those who discontinued the study prematurely. The number of deaths by Week 52 was reported. The time to death was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables. Note: Participants who discontinued from the study early had their time to death censored at Day 373 or last contact date when known to be alive (whichever occurred first), and participants with lung transplantation had their time to death censored at lung transplant date. Therefore, the number of deaths for this outcome measure differ from the overall number on deaths (reported in the Adverse Events section).
| Participants | Inhaled Treprostinil | Placebo |
|---|---|---|
| Overall Survival at Week 52 | 19 | 24 |
The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath. Percent predicted FVC is calculated based on factors such as ethnicity, sex, age, height, and weight.
| percentage of predicted | Inhaled Treprostinil | Placebo |
|---|---|---|
| Change in % Predicted FVC From Baseline to Week 52 | -1.4 (-2.2 to -0.5) | -3.8 (-4.8 to -3.1) |
The King's Brief Interstitial Lung Disease Questionnaire (K-BILD) is a self-administered, 15-item questionnaire validated for patients with interstitial lung disease (ILD) consisting of 3 domains (breathlessness and activities, psychological, and chest symptoms). Each of the 15 questions is scored from 1 (worst score) to 7 (best score). The scores for the 15 questions are added together and converted into a Total Score from 0 to 100. Higher scores indicate a better quality of life.
| scores on a scale | Inhaled Treprostinil | Placebo |
|---|---|---|
| Change in K-BILD Total Score From Baseline to Week 52 | -1.0 (-1.9 to 0.0) | -2.6 (-3.7 to -0.8) |
The DLCO measurement measures how well oxygen moves from the lungs to the blood.
| mmol/min/kPa | Inhaled Treprostinil | Placebo |
|---|---|---|
| Change in DLCO From Baseline to Week 52 | -0.2 (-0.3 to -0.1) | -0.3 (-0.4 to -0.2) |
Collected over Adverse events (AEs) were recorded throughout the course of the study from the time that each subject signed the ICF until the time screen failure was documented; until the subject withdrew consent and discontinued from the study; or until resolution, until judged by the Investigator to no longer be clinically significant, or for at least 30 days beyond the final study visit at Week 52 for up to an average of 56 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inhaled Treprostinil | 21/298 (7%) | 75/298 (25.2%) | 268/298 (89.9%) |
| Placebo | 25/295 (8.5%) | 68/295 (23.1%) | 259/295 (87.8%) |
| Event | Inhaled Treprostinil | Placebo |
|---|---|---|
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 12/298 | 22/295 |
| PneumoniaInfections and infestations | 7/298 | 13/295 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/298 | 4/295 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 3/298 | 4/295 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 2/298 | 4/295 |
| Respiratory tract infectionInfections and infestations | 4/298 | 0/295 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 4/298 | 1/295 |
| Acute myocardial infarctionCardiac disorders | 3/298 | 3/295 |
| InfluenzaInfections and infestations | 3/298 | 0/295 |
| Cardiac failure congestiveCardiac disorders | 1/298 | 2/295 |
| Event | Inhaled Treprostinil | Placebo |
|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 144/298 | 71/295 |
| HeadacheNervous system disorders | 59/298 | 35/295 |
| DiarrhoeaGastrointestinal disorders | 41/298 | 50/295 |
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 28/298 | 37/295 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 36/298 | 31/295 |
| BronchitisInfections and infestations | 30/298 | 30/295 |
| NasopharyngitisInfections and infestations | 25/298 | 30/295 |
| DizzinessNervous system disorders | 29/298 | 19/295 |
| NauseaGastrointestinal disorders | 24/298 | 26/295 |
| COVID-19Infections and infestations | 25/298 | 22/295 |
| Age, Continuous(years) | Inhaled Treprostinil | Placebo | Total |
|---|---|---|---|
| Median | 73.0 (41 to 91) | 72.0 (50 to 88) | 72.0 (41 to 91) |
| Sex: Female, Male(Participants) | Inhaled Treprostinil | Placebo | Total |
|---|---|---|---|
| Female | 60 | 58 | 118 |
| Male | 238 | 237 | 475 |
| Race (NIH/OMB)(Participants) | Inhaled Treprostinil | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 31 | 39 | 70 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 0 | 1 | 1 |
| White | 262 | 235 | 497 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 5 | 18 | 23 |
| Ethnicity (NIH/OMB)(Participants) | Inhaled Treprostinil | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 85 | 74 | 159 |
| Not Hispanic or Latino | 202 | 203 | 405 |
| Unknown or Not Reported | 11 | 18 | 29 |
| Time Since IPF Diagnosis(years) | Inhaled Treprostinil | Placebo | Total |
|---|---|---|---|
| Median | 3.375 (0.09 to 19.31) | 3.250 (0.07 to 15.23) | 3.310 (0.07 to 19.31) |
| Background Therapy at Randomization(Participants) | Inhaled Treprostinil | Placebo | Total |
|---|---|---|---|
| No Background Therapy | 73 | 73 | 146 |
| Nintedanib | 105 | 109 | 214 |
| Pirfenidone | 120 | 113 | 233 |
| Forced Vital Capacity (FVC)(mL) | Inhaled Treprostinil | Placebo | Total |
|---|---|---|---|
| Median | 2656.5 (1059 to 5487) | 2650.0 (975 to 5035) | 2652.0 (975 to 5487) |
| % Predicted FVC(percentage of predicted) | Inhaled Treprostinil | Placebo | Total |
|---|---|---|---|
| Median | 75.40 (41.0 to 129.9) | 75.80 (42.6 to 136.6) | 75.60 (41.0 to 136.6) |
4 further baseline measures are reported on the registry.
Showing the first 100 of 108 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2022 to primary completion in Jun 2025, 33 months.
Results were first posted in Oct 2026, 1 year 3 months after primary completion.
Of 24 phase 3 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 60. This study's 33 months is close to that.
Start moved once since we started tracking on Sep 25, 2026: Oct 2022 → Sep 2022, on Oct 15, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil
Idiopathic Pulmonary Fibrosis →